Background: This study was conducted to compare the efficacy and safety of rupatadine and olopatadine in patients of allergic rhinitis. Material and Methods: 100 AR (allergic rhinitis) patients. For two weeks, patients were split into two groups of 50, each of whom received 10 mg of olopatadine or 10 mg of rupatadine orally once daily. Total nasal symptom score (TNSS) was evaluated at different time intervals. Outcome was evaluated among all the patients. Results: 100 subjects were divided into two groups of 50 subjects each. Group 1 consisted of subjects receiving rupatadine while the subjects of group 2 received olopatadine. In this study, 60 subjects were males and 40 were females. In TNSS (Total Nasal Symptoms Score) at baseline, there was no statistically significant difference between the olopatadine and rupatadine groups. But after two weeks of therapy with olopatadine and rupatadine, TNSS in the olopatadine and rupatadine groups showed statistically significant differences.Conclusion: Because of its superior efficacy and safety profile, olopatadine is a preferable option for AR compared to rupatadine.